Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Aim. To study the characteristics of the daily profile of blood pressure (BP) and heart damage in patients with essential hypertension (HT), depending on the presence of obesity as well as the antihypertensive and organoprotective effects of fixed-dose combinations of amlodipine/lisinopril and bisoprolol/hydrochlorothiazide in hypertensive patients with obesity or overweight.

Material and methods. 60 patients with untreated HT, stage II, degree 1-2 (51.7% of men, aged 53.6±0.8 years) were examined. 24-hour BP monitoring and transthoracic echocardiography with calculation of myocardial stiffness parameters were performed in all patients. Hypertensive patients with obesity and overweight were randomized into groups treated with fixed-dose combinations amlodipine/lisinopril (n=25) or bisoprolol/hydrochlorothiazide (n=30). Doses of drugs were titrated until the target BP was achieved. The follow-up was 12 weeks.

Results. Patients with HT and obesity (n=28) compared with hypertensive patients without obesity (n=32) had greater systolic BP (SBP) variability at night (p<0.05) and a morning surge in SBP (p<0.01), end systolic volume (p<0.05), systolic volume (p<0.01),right ventricle anterior-posterior dimension (p<0.001), right atrium volume (p<0.01), the thickness of the interventricular septum (p<0.01) and the posterior wall (p<0.001) of the left ventricle (LV), significantly lower LV global longitudinal systolic 2D-strain (p<0.001), coefficient of diastolic and end-systolic LV elastance (p<0.05 for both). At the end of the follow-up period patients in the amlodipine/lisinopril group compared to patients in the bisoprolol/hydrochlorothiazide group had a greater decrease in the mean daily pulse BP (-10.8 vs -5.4 mm Hg, respectively; p<0.05) and variability of SBP in daytime (-2.8±0.8 vs -0.9±0.3 mm Hg, respectively; p<0.05). Only patients in the amlodipine/lisinopril group had a significant decrease in the variability of SBP (from 12.2±0.8 to 10.9±0.5 mm Hg; p<0.05) and diastolic BP (from 9.3±0.5 to 8.4±0.4 mm Hg; p<0.001) at night. Patients in the amlodipine/lisinopril group compared to patients in the bisoprolol/hydrochlorothiazide group had a greater increase in the left atrium strain (p<0.01), 2D-strain of LV and a greater decrease in the LV end diastolic stiffness (-21.39±2.45 vs -3.54±1.57 mm Hg/ml, respectively; p<0.001), the LV end systolic elastance (-16.15±2.14 vs -12.85±1.37 mm Hg/ml, respectively; p<0.05), and LV myocardial mass index (-13.2±0.9 vs -8.4±0.7 g/m2, respectively; p<0.01), the thickness of the interventricular septum and the posterior wall of the LV.

Conclusion. Untreated hypertensive obese patients in comparison with hypertensive patients without obesity have higher BP level variability during the night and early morning SBP surge, greater sizes of the heart chambers and LV myocardial wall thickness, higher LV myocardium stiffness. In obese or overweight patients with HT, a fixed-dose combination of amlodipine/lisinopril, compared with the fixed-dose combination of bisoprolol/hydrochlorothiazide, resulted in a more significant decrease in pulse BP and variability of systolic and diastolic BP at night, contributed to a more pronounced improvement in the elastic properties of the left atrium and LV myocardium and decrease in LV hypertrophy. 

About the Authors

O. D. Ostroumova
A.I. Evdokimov Moscow State University of Medicine and Dentistry; I.M. Sechenov First Moscow State Medical University
Russian Federation

MD, PhD, Professor, Chair of Faculty Therapy and Occupational Diseases, Delegatskaya ul. 20-1, Moscow, 127473;

Chair of Clinical Pharmacology and Propaedeutics of Internal Diseases, Trubetskaya ul. 8-2, Moscow, 119991


A. I. Kochetkov
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation

MD, Assistant, Chair of Faculty Therapy and Occupational Diseases,

Delegatskaya ul. 20-1, Moscow, 127473

M. V. Lopukhina
E.O. Mukhin Municipal Clinical Hospital
Russian Federation

MD, PhD, Head of Department of Functional Diagnostics,

Federativnii prospekt 17, Moscow, 111399


1. Boytsov S.A.,DeevA.D., Shalnova S.A. Mortality and risk factors for non-communicable diseases in Russia: Specific features,trends, and prognosis. TerapevticheskiyArkhiv. 2017;89(1):5-13. (In Russ.) [Бойцов С.А., Деев А.Д., Шальнова С.А. Смертность и факторы риска неинфекционных заболеваний в России: особенности, динамика, прогноз. Терапевтический Архив. 2017;89(1):5-13].

2. Samorodskaja I.V., Bolotova E.Y., Boytsov S.A. Paradox of obesity and cardiovascular mortality. Kardiologiia 2015;55(9):31-6. (In Russ.) [Самородская И.В., Болотова Е.В., Бойцов С.А. Парадокс ожирения и сердечно-сосудистая смертность. Кардиология. 2015;55(9):31-6].

3. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and ofthe European Society of Cardiology (ESC).JHypertens. 2013;31:1281-357.

4. Brady T.M. The Role of Obesity in theDevelopment of Left VentricularHypertrophyAmong Children and Adolescents. Curr Hypertens Rep. 2016;18(1):3.

5. Chazova I.E., Ratova L.G., Boitsov S.A., Nebieridze D.V. Recommendations for the management of arterial hypertension Russian Medical Society ofArterialHypertension and Society of Cardiology ofthe Russian Federation. Sistemnye Gipertenzii. 2010;3:5-26. (In Russ.) [Чазова И.Е., Ратова Л.Г., Бойцов С.А., Небиеридзе Д.В. Диагностика и лечение артериальной гипертензии (Рекомендации Российского медицинского общества по артериальной гипертонии и Всероссийского научного общества кардиологов). Системные Гипертензии. 2010;3:5-26].

6. O’Brien E., Parati G., Stergiou G., et al., on behalf ofthe European Society ofHypertensionWorking Group on Blood Pressure Monitoring. Guidelines European Society of Hypertension Position Paper on Ambulatory Blood Pressure Monitoring. Journal of Hypertension. 2013;31:1731-68.

7. LangR.M., Badano L.P.,Mor-AviV., et al.Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14.

8. Mor-AviV., Lang R.M., Badano L.P., et al. Current and evolving echocardiographic techniques forthe quantitative evaluation of cardiac mechanics:ASE/EAE consensus statement on methodology and indications endorsed by the Japanese Society of Echocardiography. Eur J Echocardiogr. 2011;12(3):167-205.

9. Verdecchia P.,Angeli F.,GattobigioR., et al. Impact ofblood pressure variability on cardiac and cerebrovascular complications in hypertension. American journal of hypertension 2007;20(2):154-61.

10. An H.J., Kim W., Kang C., et al., Other Korean Ambulatory Blood Pressure Registry Investigators. Obesity increases blood pressure variability during the night. J Korean Soc Hypertens. 2014;20(1):1-7.

11. Ostroumova O.D., Bondarets O.V., Guseva T.F., et al. The morning rise in blood pressure: clinical implications аnd opportunities of candesartan in their correction. Kardiologicheskij Vestnik. 2015;3:76-80. (InRuss.) [Остроумова О.Д., Бондарец О.В., Гусева Т.Ф., и др. Утренние подъемы артериального давления: клиническое значение и возможности кандесартана в их коррекции. Кардиологический Вестник. 2015;3:76-80ъ.

12. Tutal E., Sayın B., Ertugrul D.T., et al. Is there a link between hyperuricemia, morning blood pressure surge, and non-dipping blood pressure pattern in metabolic syndrome patients? International Journal of Nephrology and Renovascular Disease. 2013;6(1):71-7.

13. Mangner N., Scheuermann K., Winzer E., et al. Childhood obesity: impact on cardiac geometry and function. JACC: Cardiovascular Imaging. 2014;7(12):1198-205.

14. Crendal E.,Walther G.,VinetA., et al. Myocardial deformation and twist mechanics in adults with metabolic syndrome: impact of cumulative metabolic burden. Obesity. 2013;21(12):E679-86.

15. GonНalves N., Silva A.F., Rodrigues P.G., et al. Early cardiac changes induced by a hypercaloric Western-type diet in “subclinical” obesity. American Journal of Physiology-Heart and Circulatory Physiology. 2016;310(6):H655-66.

16. Domanski M.J., Davis B.R., Pfeffer M.A., et al. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension. 1999;34:375-80.

17. Benetos A., Safar M., Rudnichi A., et al. Pulse pressure. Hypertension 1997:30(6);1410-5.

18. Dolan E., StantonA.V., Thom S., et al.;ASCOT Investigators.Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients - anAnglo-Scandinavian cardiac outcomes trial substudy. J Hypertens. 2009;27(4):876-85.

19. Ersh I.R. Zaicev V.I., Romanchuk E’.V., et al. Efficacy of long-term therapy with the Equator in patients with arterial hypertension in ambulatory conditions. Mezhdunarodnye Obzory: Klinicheskaya Praktika I Zdorov’e.2014;2(8):74-86. (InRuss.) [ЕршИ.Р., Зайцев В.И., Романчук Э.В., и др. Эффективность длительной терапии препаратом Экватор больных артериальной гипертензией в амбулаторных условиях. Международные Обзоры: Клиническая Практика и Здоровье. 2014;2(8):74-86].

20. Morozov S.N., Donskaja A.A., Morozova E.A. The effectiveness of the equator treatment of patients with arterial hypertension (evidence from Yakutsk). Yakutskij Medicinskij Zhurnal. 2008;4(24):9-12. (In Russ.) [Морозов С.Н., ДонскаяА.А., Морозова Е.А. Эффективность терапии экватором больных с артериальной гипертонией (на примере г. Якутска). Якутский Медицинский Журнал. 2008;4(24):9-12].

21. Kakhramanova S.M., Bahshaliev A.B. Antihypertensive and cardioprotective efficacy of the Equator in patients with essential hypertension. “Russian National Congress of Cardiologists. Improving the quality and availability of cardiac care (Congress materials)”. Kardiovaskulyarnaya Terapiya i Profilaktika. 2008;7(6)b Suppl. 1:173. (In Russ.) [Кахраманова С.М., Бахшалиев А.Б. Антигипертензивная и кардиопротективная эффективность Экватора у больных эссенциальной гипертонией. «Российский национальный конгресс кардиологов.Повышение качества и доступности кардиологической помощи (материалы конгресса)». Кардиоваскулярная Терапия и Профилактика. 2008;7(6)б Приложение 1:173].

22. Ageev F.T., Ovchinnikov A.G., Serbul V.M., Belenkov Yu.N. Left ventricle hypertrophy: the role of the renin-angiotensin system. Kardiovaskulyarnaya Terapiya i Profilaktika. 2008;7(2):98-108. (In Russ.) [Агеев Ф.Т., Овчинников А.Г., Сербул В.М., Беленков Ю.Н. Гипертрофия левого желудочка: роль ренин-ангиотензиновой системы. Кардиоваскулярная Терапия и Профилактика. 2008;7(2):98-108].

23. Chudinovskih Ju.A., Eremeeva M.V., Suhacheva T.V., et al. The new data on the mechanisms of the effect of pharmacological treatment on myocardial hypertrophy in patients with obstructive form of hypertrophic cardiomyopathy. Klinicheskaya Fiziologiya Krovoobrashheniya. 2013;1:12-8. (In Russ.) [Чудиновских Ю.А., Еремеева М.В., Сухачева Т.В., и др.Новые данные о механизмах влияния фармакологического лечения на гипертрофию миокарда у пациентов с обструктивной формой гипертрофической кардиомиопатии. Клиническая Физиология Кровообращения. 2013;1:12-8].

24. Krikunov P.V.,Vasjuk Ju.A., Kopeleva M.V., Krikunova O.V. Left ventricle hypertrophy as a targetfortherapeutic intervention.Diagnostic and treatment aspects. Serdce. 2008;6(7):324-34. (In Russ.) [КрикуновП.В., Васюк Ю.А., Копелева М.В., Крикунова О.В. Гипертрофия левого желудочка как мишень для терапевтического вмешательства. Особенности диагностики и лечения. Сердце. 2008;6(7):324-34].

25. Xiang S., Zhang N., Yang Z., et al. Achievement of a target dose of bisoprolol may not be a preferred option for attenuating pressure overload‐induced cardiac hypertrophy and fibrosis. Experimental and Therapeutic Medicine. 2016;12(4):2027-38.

26. KaiH., Kaneyuki M., Shihara M., et al.,forthe MAPPY Study Investigators. Reduction in morning blood pressure is a key factor for ameliorating urinary albumin excretion in patients with morning hypertension irrespective of treatment regimen. Circulation Journal. 2013;77(6):1551-7.

27. Barron A.J., Hughes A.D., Sharp A., et al. Long-term antihypertensive treatment fails to improve E/e' despite regression ofleft ventricular mass: anAnglo-Scandinavian cardiac outcomes trial substudy.Hypertension. 2014;63(2):252-8.

28. Diez J., Laviades C., Mayor G., et al. Increased serum concentrations of procollagen peptides in essential hypertension: relation to cardiac alterations. Circulation. 1995;91:1450-6.

29. Xing S.S., TanH.W., Bi X.P., et al. Felodipine reduces cardiac expression ofIL-18 and perivascularfibrosis in fructose-fed rats. Mol Med. 2008;14(7-8):395-402.

30. Fukui M., Goda A., Komamura K., et al. Changes in collagen metabolism account for ventricularfunctionalrecovery following beta-blockertherapy in patients with chronic heartfailure.Heart and Vessels. 2016;31(2):173-82.

For citation:


Views: 357

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)